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Introduction: Darunavir is a second-generation protease inhibitor and is registered for the 42 
treatment of human immunodeficiency virus (HIV) -1 infection. The aim of this study was to 43 
develop and validate a darunavir population pharmacokinetic model based on data from daily 44 
practice.  45 
Methods: Datasets were obtained from two hospitals: ASST Fatebenefratelli Sacco 46 
University Hospital, Italy (hospital A) and University Medical Center Groningen, The 47 
Netherlands (hospital B). A pharmacokinetic model was developed using data from the largest 48 
dataset using the iterative two-stage Bayesian procedure within the MWPharm software 49 
package. External validation was conducted using data from the smaller dataset with Passing-50 
Bablok regression and Bland-Altman analyses.  51 
Results: In total, data from 198 patients from hospital A and 170 patients from hospital B 52 
were eligible for inclusion. A one-compartment model with first-order absorption and 53 
elimination resulted in the best model. The Passing-Bablok analysis demonstrated a linear 54 
correlation between measured concentration and predicted concentration with r2 = 0.97 55 
(p<0.05). The predicted values correlated well with the measured values as determined by a 56 
Bland-Altman analysis and were overestimated by a mean value of 0.12 mg/L (range 0.23-57 
0.94 mg/L). 98.2% of the predicted values were within the limits of agreement.  58 
Conclusion: A robust population pharmacokinetic model was developed which can support 59 
therapeutic drug monitoring of darunavir in daily outpatient settings. 60 
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Darunavir is a second generation protease inhibitor and is registered for the treatment of 64 
human immunodeficiency virus (HIV) -1 infection in therapy-naïve and therapy-experienced 65 
adults and paediatric patients aged ≥6 years.1, 2 Once-daily dosage of 800 mg darunavir is 66 
approved for use in treatment-naïve patients and a twice-daily dosage of 600 mg darunavir is 67 
approved for use in treatment-experienced patients.3 Darunavir is co-administered with 100 68 
mg ritonavir or with 150 mg cobicistat in order to improve its exposure, as darunavir is almost 69 
exclusively metabolized by cytochrome P450 3A4.4-6 In healthy volunteers, darunavir 70 
exposure increased by 30% when ingested with food, irrespective of the type of food.7    71 
For darunavir, a wide inter-patient pharmacokinetic variability has been observed.2, 8, 9 This 72 
pharmacokinetic variability can be attributed to treatment non-adherence, co-medication 73 
interactions, variability of cytochrome P450 3A4 iso-enzyme activity and patient 74 
demographics.2, 5, 8, 10 Pharmacokinetic variability may have detrimental effects by causing 75 
suboptimal darunavir concentrations and drug resistance resulting from the propagation of 76 
HIV-1 pseudo-species with protease mutations.11 Therapeutic drug monitoring (TDM) 77 
potentially is a powerful tool to optimize treatment and to prevent drug resistance if a 78 
correlation exists between drug concentrations and (adverse) effects, if a drug has large inter-79 
individual pharmacokinetic variability, or if a drug has a narrow therapeutic index.12 For 80 
darunavir, a correlation exists between drug concentrations and effects 1, 5 and therefore TDM 81 
has the potential to optimise efficacy in standard care. In Dutch daily practice, the trough 82 
concentration of darunavir is often used to help physicians determining the follow-up 83 
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cases of: drug-drug interactions, renal or hepatic morbidity, pregnancy administration of drug 85 
doses not commonly used, virologic failure, suspicion of non-adherence, and adverse events.14  86 
Collection of multiple plasma samples during one dosing interval to measure total drug 87 
exposure is time-consuming, expensive and burdensome to patients and to the health care 88 
system in a routine care setting. Furthermore, trough concentrations, the most frequently used 89 
pharmacokinetic parameter in TDM, is not always captured due to varying dosing schedules 90 
of patients in daily practice. A population pharmacokinetic model can provide a solution as it 91 
can be used to predict the (trough) plasma concentration profile of darunavir with a limited 92 
number of samples.2, 8 Two population pharmacokinetic models with different results were 93 
developed: one based on a one-compartment model 2 and one suggesting a two-compartment 94 
model.8 The aim of this study was to investigate which kind of model best describes the data 95 
from our outpatient setting by using the two previously published models prior to our own 96 
modelling experiment and to subsequently develop and validate a population pharmacokinetic 97 
model with data from daily practice, in order to predict darunavir trough levels in an HIV 98 
outpatient setting using user friendly software. 99 
Materials and Methods 100 
DATA COLLECTION 101 
This study was conducted using two datasets from two hospitals: ASST Fatebenefratelli 102 
Sacco University Hospital, Milano, Italy (ASST) and the University Medical Center 103 
Groningen, The Netherlands (UMCG). All measured darunavir plasma concentrations were 104 
extracted from the ASST electronic patient database (April 2015 - August 2017) and from the 105 
UMCG electronic patient database (January 2010 - May 2017). Based on the size, the ASST 106 
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the Ethics Committee was deemed unnecessary for ASST because, under Italian law, such an 108 
approval is required only for prospective clinical trials investigating medical products for 109 
clinical use. The ethical review board of the UMCG evaluated the study and waived the need 110 
for written informed consent due to the retrospective nature of the study (METc 2015.010). 111 
This was a retrospective data record review; the data were collected for clinical purposes and 112 
were anonymized for the study.  113 
Data of patients ≥18 years of age and treated with darunavir were eligible for inclusion in this 114 
study. Both datasets were comprised of retrospectively collected data from HIV infected 115 
patients using darunavir/ritonavir 600/100 mg twice-daily or 800/100 mg once-daily. The 116 
following data were extracted from the medical records of the participants: sex, age, weight, 117 
height, serum creatinine concentration, darunavir dosage, time of darunavir intake, time of 118 
blood sampling and darunavir plasma concentration. The weight obtained during the 119 
outpatient visit of drug level measurement was documented in the research database; for 120 
serum creatinine concentration, the corresponding value during the visit of drug level 121 
measurement or within a period of ±15 days was documented. Darunavir plasma 122 
concentrations were excluded if the time of drug intake or time of blood sampling was 123 
unknown and if the measured darunavir concentration was below the lower limit of 124 
quantification (< 0.2 mg/L for both hospitals). In cases where the height or weight of the 125 
patient were not documented, the average height (male: 1.80 m; female: 1.70 m) and weight 126 
(male: 80 kg; female 70 kg) according to the Dutch Central Bureau of Statistics (CBS) or 127 
average height (male: 1.75 m; female: 1.65 m) and weight (male: 75 kg; female: 65 kg) 128 
according to the Italian National Institute of Statistics (ISTAT) were inserted. 15, 16 The 129 
addition of mean weight and height values for missing data was accepted up to 10% per 130 
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patients were excluded. Darunavir plasma concentrations were analysed by a validated liquid 132 
chromatography-tandem mass spectrometry method. 17  133 
POPULATION PHARMACOKINETIC MODEL DEVELOPMENT 134 
All pharmacokinetic calculations and modelling were performed using the MWPharm 135 
software package (version 3.82; Mediware, Zuidhorn, The Netherlands).18 The dataset with 136 
the largest population in terms of highest number of unique patients (hospital A) was chosen 137 
for pharmacokinetic model development and the dataset with the lower number of unique 138 
patients (hospital B) was used as the external validator set. The development dataset was 139 
imported in MWPharm to develop a population pharmacokinetic model using an iterative 140 
two-stage Bayesian (ITSB) procedure (the KinPop model of the MWPharm software 141 
package).19 The modelling was performed with the following estimated pharmacokinetic 142 
parameters: total body clearance (CL), volume of distribution (V) and oral absorption rate 143 
constant (Ka). CL was calculated using the equation:  = 	 × 	
  + 	 ×144 
	,where CLm is metabolic clearance (in liters per hour per 70 kg body weight), BW is 145 
body weight (kilograms), fr is the ratio of the renal clearance of darunavir and the creatinine 146 
clearance, CLcr is the creatinine clearance calculated with the Chronic Kidney Disease 147 
Epidemiology collaboration (CKD-EPI) formula (converted to unit liter/hour) [20]. V was 148 
calculated using the equation: V	 = 	V1	 × 	LBMc, where V1 is the volume of distribution (in 149 
liters per 70 kg LBMc) and LBMc is the lean body mass corrected, calculated with	LBMc	 =150 
	LBM	 +	(BW–LBM) × fd, where LBM is calculated from 50.0	 + 	0.9 × (Height– 152)	 for 151 
males and 45.5	 + 	0.9 × (Height– 152)	for females. 21 Height is body height in cm, and fd is 152 
a dimensionless parameter describing the degree of distribution into fatty tissue. 22 For the 153 
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intercompartmental clearance (CL12, in liter per hour per 70 kg body weight) and volume of 155 
distribution of the peripheral compartment (V2, in liters per kg LBMc). Pharmacokinetic 156 
parameters were assumed to be log-normally distributed and the residual error was assumed to 157 
be normally distributed and equal to the standard deviation (SD) of the assay which was 158 
estimated as0.2	 + 	0.05 × C, where C is the observed darunavir plasma concentration.  159 
ITSB needed initial estimates for each population parameter (mean and standard deviation 160 
(SD)) to start the iterative process. 19 In order to perform the ITSB procedure for the 161 
development of a one-compartment model with first-order elimination, initial population 162 
pharmacokinetic parameters from Arab-Alameddine et al. and darunavir Summary of Product 163 
Characteristics (SPC) were used 2, 23 (supplement 1,http://links.lww.com/TDM/A279). 164 
Subsequently, the development of a two-compartment model for darunavir was also explored 165 
based on initial pharmacokinetic data from Molto et al. and darunavir SPC 8, 23 (supplement 166 
1,http://links.lww.com/TDM/A279). 167 
A stepwise approach was used to find a model that fitted the darunavir data best, comparing 168 
one- and two-compartment models. The goodness-of-fit of the newly designed population 169 
pharmacokinetic models were evaluated using the Akaike Information criterion (AIC). 19 170 
Selection of a one- or two-compartment model was based on (1) the lowest value of the AIC, 171 
and (2) the plausibility of the pharmacokinetic parameters. A drop in the AIC of 2 or more 172 
was considered to be the threshold for a better fitting model. 24 Furthermore, different values 173 
for fd and fr were inserted in order to observe the best fit based on AIC.  174 
The KinPop module of the MWPharm software package has three settings for the inclusion of 175 
pharmacokinetic parameters in a model: by iterative two-stage Bayesian analysis 176 
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Bayesian”; FPB), or set to a fixed value (“fixed”). In the modelling procedure of the one-178 
compartment model, the population pharmacokinetic parameters CLm, V1 and Ka were first 179 
set on fixed values. The same pharmacokinetic parameters were also set on fixed values for 180 
the modelling procedure of the two-compartment model in addition to CL12 and V2. The first 181 
step in developing the model was to set all parameters fixed to the literature values in 182 
supplement 1 and change one parameter at a time to either Bayesian or to the fixed value. The 183 
parameter with the lowest AIC was chosen for the next step. In step 2, the parameter with the 184 
lowest AIC was set to Bayesian and all other parameters were changed one by one to 185 
Bayesian. These steps were repeated in the next cycle using previous population parameters 186 
until the set with population parameters best fitting the data was found. 187 
For the final parameter set, the nonparametric 95% confidence intervals of the population 188 
parameters and their inter-individual standard deviations were estimated by bootstrap analysis 189 
(n=1,000), which could be considered as a resampling technique for internal validation. 190 
POPULATION PHARMACOKINETIC MODEL VALIDATION 191 
External validation was performed by Bayesian fitting of the pharmacokinetic model to each 192 
individual in the validator dataset, using the previously developed model, as this provides the 193 
strongest evidence for model validation. The Kinpop module in MW\Pharm was used with 194 
one cycle set as a maximum. In this setting, the algorithm implemented in the MW\Pharm 195 
software determines the predictive power of a population pharmacokinetic model (a model's 196 
ability to predict serum levels of an individual patient), as opposed to the iterative procedure 197 
for the fitting of a new population pharmacokinetic model to population data. Passing-Bablok 198 
regression and Bland-Altman analyses were used to assess the agreement between the 199 








Copyright © 201 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of





For the bootstrap analysis and external validation, the final model was used, and if this model 201 
appeared to be inappropriate, the second-best logical model was also used for the bootstrap 202 
analysis and external validation. 203 
P values of ≤0.05 were considered statistically significant. All statistical analyses were either 204 
performed as part of the MWPharm population analysis or computed using SPSS version 23 205 
(IBM, Armonk, NY, USA). 206 
Results 207 
DATASET 208 
198 unique patients with a total of 198 samples for hospital A and 170 unique patients with a 209 
total of 170 samples for hospital B were eligible for inclusion (supplement 210 
2,http://links.lww.com/TDM/A280). The demographic characteristics of both patient 211 
populations were comparable (table 1). The percentage of missing values did not reach the 212 
threshold of 10% in both databases. No data was missing in the dataset of hospital A. In the 213 
dataset of hospital B, the weight of 14 participants (8.2%) and the height of 1 participant 214 
(0.6%) were not documented and therefore the average height and weight according to the 215 
CBS were used in these cases.  216 
POPULATION PHARMACOKINETIC MODEL 217 
The settings and results of the different one- and two-compartment submodels developed in 218 
order to find the model with the best goodness of fit are shown in supplement 219 
3,http://links.lww.com/TDM/A281. Due to the absence of data on drug concentrations 220 
following parenteral darunavir administration as a comparison for oral administration to 221 
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value of 0.82. 23 A one-compartment model with a first-order absorption and elimination, a 223 
distribution to fatty tissue factor (fd) of 5 and a fr value of zero resulted in the best model. The 224 
addition of a second compartment did not significantly improve the fit based on AIC. In our 225 
dataset, the second compartment was estimated as 0.051 L/kg, which is negligible as a 226 
significant peripheral compartment. 227 
The one-compartment model with only CLm set on Bayesian (Model 1) had the lowest AIC 228 
value (945.31). This model implies that the volume of distribution (in L/kgLBMc) is the same 229 
for each patient, which does not seem logical. For that reason, the model with the second-best 230 
AIC value (Model 2) was also externally validated. This model had an AIC = 1584.89 with 231 
both CLm and Vd set on Bayesian. The population pharmacokinetic model parameters of both 232 
models are shown in table 2. The modelling process of the different values for fat distribution 233 
(fd) and the in- and exclusion of the fr are shown in supplement 234 
4,http://links.lww.com/TDM/A282. 235 
EXTERNAL VALIDATION 236 
For both models 1 and 2, an external validation was performed with the dataset from hospital 237 
B. The agreement between the measured concentration (Cmeasured) and the predicted 238 
concentration (Cpredicted) was assessed in a Passing-Bablok analysis, shown in figure 1. The 239 
Passing-Bablok analysis demonstrated a positive linear correlation between Cmeasured and 240 
Cpredicted with r2 = 0.85 (P<0.05) for Model 1 and r2 = 0.97 (P<0.05) for Model 2. Predicted 241 
values correlated well with measured values for both models as determined by Bland-Altman 242 
analysis (figure 2). For Model 1, predicted values were overestimated by a mean value of 0.07 243 
mg/L (range 1.08-1.89 mg/L), of which 92.3% of the total predicted values were within the 244 
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0.12 mg/L (range 0.23-0.94 mg/L), of which 98.2% of the total predicted values were within 246 
the limits of agreement. Based on plausibility of the computed pharmacokinetic data as well 247 
as the better agreement between measured and predicted concentrations, Model 2 was chosen 248 
as final model. 249 
Discussion 250 
In this study we evaluated two published population pharmacokinetic models and 251 
subsequently developed a new population pharmacokinetic model for darunavir that better 252 
described our population and provided us the opportunity to estimate darunavir trough 253 
concentration and that therefore was considered preferable for routine use. We showed that 254 
darunavir concentrations from the validation set can be predicted with this population 255 
pharmacokinetic model with a mean overestimation of 0.12 mg/L (range 0.23-0.94 mg/L). 256 
The observed range could potentially be further narrowed by using more sophisticated 257 
pharmacokinetic software allowing the addition of other covariates. However, the developed 258 
model is sufficient for daily outpatient setting since 98.2% of the total predicted values were 259 
within the limits of agreement. The robustness of the developed population pharmacokinetic 260 
model was demonstrated with the dataset of hospital B using Passing-Bablok regression (r2 = 261 
0.97; P<0.05).     262 
Consistent with the findings of Arab-Alameddine et al., 2 a one-compartment model with first-263 
order absorption and elimination resulted in the best fit when using our patient data. The 264 
selection of the final population pharmacokinetic model was not merely based on AIC but 265 
was also selected based on plausibility of the computed pharmacokinetic data as well as on 266 
the agreement between measured and predicted concentrations in the external validation. For 267 
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submodel less dependent on patient factors such as body weight and more on literature 269 
values,2 which did not seem logical. Therefore, the model with both CLm and Vd set on 270 
Bayesian (Model 2), based on AIC in combination with the plausibility of the computed data, 271 
was chosen for external validation. In addition, the agreement between measured and 272 
predicted concentrations in the external validation (figures 1 and 2) was markedly better for 273 
Model 2 than for Model 1, and therefore Model 2 was chosen as final model.  274 
The submodel with also Ka set on Bayesian resulted in a poorer fit, which could be due to the 275 
low number of darunavir samples drawn in the absorption phase; 0-4 h after drug intake. 5 276 
Further, a ratio of fat distribution (fd) of 5 and the omission of fr (fixed at a value of zero) 277 
provided better AIC scores. A possible explanation of a better fit with a fat distribution ratio 278 
of 5 might again be the relatively high lipophilicity of darunavir. 25 The improvement of the 279 
model with the omission of fr is not a remarkable finding since darunavir is mainly eliminated 280 
by the liver (80%) and the renal elimination is negligible, 23 therefore, fr appears not to be a 281 
significant covariate.  282 
Due to the relative high lipophilicity of darunavir, 25 a two-compartment population 283 
pharmacokinetic model would be expected to demonstrate a better fit. However, the addition 284 
of a second compartment did not improve the fit. This suggests that there is insufficient 285 
information in the used dataset to parameterize a two-compartment model. This could be a 286 
result of suboptimal blood sampling time points post-administration, which is required for the 287 
estimation of parameters for a two-compartment model. Further, the estimation of parameters 288 
for a two-compartment model after extravascular administration with first-order absorption is 289 
difficult since the rate constants of distribution and absorption usually have the same order of 290 
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sampling may occur due to practical convenience. For the development of a two-compartment 292 
pharmacokinetic model, richer data is more convenient in contrast to the currently used scarce 293 
real-life outpatient data.  294 
For the development and validation of this population pharmacokinetic model, observational 295 
datasets retrieved from standard care settings were utilized. The use of observational datasets 296 
has advantages compared to experimental datasets due to economic- and ethical reasons; 297 
although it can often include larger number of patients and minimize risks and discomfort for 298 
the patients, it also has drawbacks. The major disadvantages of observational datasets are 299 
missing data and inaccurate data due to documentation errors. 26 Despite these drawbacks, the 300 
use of observational datasets was preferred in relation to the aim of the present study. The 301 
population pharmacokinetic model was developed for utilization in a real-life HIV outpatient 302 
setting. Data retrieved from an experimental setting would lack the high inter-patient 303 
variability which is apparent in standard care. Furthermore, a study showed that relatively 304 
small errors (e.g. up to 25% of the being data erroneous) in data registration have negligible 305 
influence on population pharmacokinetic modelling, 26 which also justifies the use of 306 
observational datasets from two hospitals for the development of a population 307 
pharmacokinetic model and its validation. Larger errors could still have a significant effect on 308 
the population pharmacokinetic modelling process, 26 therefore, patients with undetectable 309 
darunavir concentrations (≤ 0.2 mg/L), or unknown weight, height, unknown time of drug 310 
intake or time of sample collection above the 10% cut off were excluded. Regarding the 311 
modelling approach utilized for this study, while nonlinear mixed effects modelling is a more 312 
standard approach for sparse PK data, ITSB was chosen for this study because it allows for 313 
using body weight and serum creatinine level as continuously changing covariates. 314 
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The Bland-Altman analysis (figure 2) reveals that the relatively small observed 316 
overestimation of the current model primarily occurs in lower darunavir concentrations. One 317 
explanation could be the relatively high assay error at lower concentrations. Another 318 
explanation may be that overestimation at a lower concentration can be an indicator for 319 
multiple-compartment pharmacokinetics, due to saturation of peripheral compartments. 320 
Unfortunately, our data were not sufficiently informative for fitting to a two-compartment 321 
model as discussed before. A third explanation might be the occurrence of underlying 322 
confounders, such as food intake and pharmacogenomics, which are not included in the 323 
current model. An additional explanation could be the saturation of metabolism at higher 324 
concentrations resulting in a higher clearance at low concentrations than predicted. However, 325 
the overestimation is within the error of the assay and does not significantly influence the 326 
analytical results. Furthermore, 98.2% of the total predicted values were estimated within the 327 
limits of agreement, justifying the use of this model in daily practice. 328 
In standard care, darunavir concentrations are measured when indicated 14 and subsequently 329 
the time-adjusted darunavir trough concentrations can be predicted using the currently 330 
developed population pharmacokinetic model. The time-adjusted darunavir trough 331 
concentrations are subsequently dichotomized as either ‘above’ or ‘below’ cut-off values in 332 
accordance with the local treatment protocol. 13 The used cut-off values do not represent the 333 
minimal effective concentrations but are used in standard care as cut-off values for follow-up. 334 
A darunavir trough concentration below 1.07 mg/L for the once-daily dosage or below 2.60 335 
mg/L for the twice daily dosage is an indication for follow-up. This follow-up could consist of 336 
repeating the plasma drug concentration measurement on a new occasion, additional food 337 
intake advice and additional questions and guidance concerning therapy adherence. 13, 14 In 338 
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measured concentrations can be utilized directly according to the treatment protocol. 340 
However, outpatient setting blood collection is not performed at optimal time points in most 341 
cases due to practical reasons. In those cases, the population pharmacokinetic model 342 
developed in this study could provide the opportunity to translate the drug concentrations 343 
collected at suboptimal timepoints into trough concentrations. In order to investigate the 344 
pharmacokinetics of darunavir more in-depth and to investigate the potential contribution of 345 
other confounders to darunavir pharmacokinetics, denser pharmacokinetic sampling in 346 
combination with sophisticated software packages such as NONMEM (nonlinear mixed effect 347 
modelling) will be more suitable. However, that was not within the scope of the current study. 348 
In our opinion, TDM can be a useful tool for clinicians to optimize treatment especially when 349 
used in conjunction with disease related parameters such as viral load, CD4+ cell count, and 350 
clinical judgement.   351 
A strength of the current study is that we used a large number of patient data from two 352 
different hospitals, one for the development and the other for the validation of the darunavir 353 
population pharmacokinetic model. Since the current aim is the utilization of the model in an 354 
outpatient setting, another strength is the use of data retrieved from the target population. A 355 
limitation of this study is that potentially non-adherent patient or patients with food intake 356 
problems were included, which may have introduced selection bias and increased variance. 357 
However, this was inevitable as these patients in particular are selected for TDM, since non-358 
adherence or inadequate concomitant food intake are indications for TDM (bias by 359 
indication).14 Another limitation is the low number of blood samples in the absorption phase 360 
(0 – 4 h). Due to this gap of information, it was not possible to parameterize the absorption 361 
constant in the population pharmacokinetic model, leading to a fixed value based on 362 
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into account in our model. However, the aim of this study was not to investigate the 364 
pharmacokinetics of darunavir in depth, for which, as aforementioned, a different approach 365 
and study design would have been required. This pharmacokinetic model developed and 366 
validated herein can pragmatically estimate darunavir trough concentrations in daily practice 367 
and will suffice to use in routine TDM. 368 
 369 
Conclusion 370 
A new one-compartment population pharmacokinetic model for darunavir was developed and 371 
externally validated. This model is robust and is applicable for TDM of darunavir in daily 372 
outpatient setting. 373 
 374 
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 456 
Figure Legends 457 
Figure 1. Passing – Bablok regression. The plot shows the agreement between Cmeasured and 458 
Cpredicted, predicted with the population pharmacokinetic model (dashed lines, 95% confidence 459 
interval [CI]). A: Model 1, B: Model 2 460 
Figure 2. Bland – Altman plot. The Bland-Altman plot shows the agreement between Cmeasured 461 
and Cpredicted estimated with the final population pharmacokinetic model. Mean of all: the 462 
mean concentration of Cmeasured and Cpredicted. The dashed lines represent: Upper Limit of 463 
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Table 1. Patient demographics hospitals A and B. 




No. (%) of patients by sex   
     Male 141 (71) 142 (84) 





54 (24-74) 52 (28-73) 
Weight (kg)
a 
72.0 (40-123) 74.5 (41-120) 
Height (cm)
a 
173.0 (150-193) 179.5 (151-202) 
Body mass index (kg/m2)a 24.6 (16.9-35.3) 24.0 (15.0-40.2) 
Serum creatinine conc. (µmol/L)
a,b
 83.5 (44.2-230.7)  85.5 (36.0-329.0) 
Dosage 800/100 once daily 162 (82) 144 (85) 
Dosage 600/100 twice daily 36 (18) 26 (15) 
Dose/mean wt (once-daily) (mg/kg)
a 
11.0 (6.5-20.0) 10.6 (6.6-19.5) 
Dose/mean wt (twice-daily) (mg/kg)
a 
8.3 (4.9-15.0) 7.9 (5.0-14.6) 
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Table 2. Final population pharmacokinetic parameters.  
Parameter 
 
Model 1  
AIC = 945.31 
Model 2 
AIC = 1584.89* 
Mean (95% CI)  SD (95% CI) Mean (95% CI)  SD (95% CI) 
CLm (L/h/70kgBW) 11.22 (9.54 – 
13.38) 
12.11 (8.39 – 
16.59) 
9.47 (8.24 – 
10.65) 
6.19 (4.85 – 7.76) 





 1.04 - 1.04 - 
F
b
 0.82 - 0.82 - 
fr 0 - 0 - 
Fat distribution 5 - 5 - 
a 
Literature value (2); 
b
 Literature value from SPC(17); 
c
 set on fixed value; SD: standard deviation; (95% CI); 95% 
confidence interval; CLm: metabolic clearance; Vd: volume of distribution; Ka: first order absorption constant; F: 
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Figure 1. Passing – Bablok regression. The plot shows the agreement between Cmeasured and Cpredicted, predicted with the population pharmacokinetic 
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Figure 2. Bland – Altman plot. The Bland-Altman plot shows the agreement between Cmeasured and Cpredicted estimated with the final population 
pharmacokinetic model. Mean of all: the mean concentration of Cmeasured and Cpredicted. The dashed lines represent: Upper Limit Of Agreement and Lower 
Limit Of Agreement (± 2 x standard deviation). A: Model 1, B: Model 2 
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